Advertisement

Delivery of Therapeutics to the Lung

  • Dominique N. Price
  • Pavan Muttil
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1809)

Abstract

Pulmonary delivery in animal models can be performed using either direct administration methods or by passive inhalation. Direct pulmonary delivery requires the animal to be endotracheally intubated, whereas passive delivery uses a nose-only or a whole-body chamber. Endotracheal delivery of therapeutics and vaccines allows investigators to deliver the payload directly into the lung without the limitations associated with passive pulmonary administration methods. Additionally, endotracheal delivery can achieve deep lung delivery without the involvement of other exposure routes and is more reproducible and quantitative than passive pulmonary delivery in terms of accurate dosing. Here we describe the endotracheal delivery of both liquids and dry powders for preclinical models of treatment and exposure.

Key words

Pulmonary delivery Endotracheal delivery Intratracheal delivery Intubation Insufflation MicroSprayer Dry powder 

References

  1. 1.
    Patton JS, Byron PR (2007) Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 6:67–74. https://doi.org/10.1038/nrd2153CrossRefPubMedGoogle Scholar
  2. 2.
    Hickey AJ (2013) Back to the future: inhaled drug products. J Pharm Sci 102:1165–1172. https://doi.org/10.1002/jps.23465CrossRefPubMedGoogle Scholar
  3. 3.
    Price DN, Kunda NK, McBride AA, Muttil P (2016) Vaccine preparation: past, present, and future. In: Drug delivery systems for tuberculosis prevention and treatment. John Wiley & Sons, Ltd, Chichester, pp 67–90. https://doi.org/10.1002/9781118943182.ch4CrossRefGoogle Scholar
  4. 4.
    Garcia-Contreras L, Hickey AJ (2003) Aerosol treatment of cystic fibrosis. Crit Rev Ther Drug Carrier Syst 20:317–356. https://doi.org/10.1615/CRITREVTHERDRUGCARRIERSYST.V20.I5.10CrossRefPubMedGoogle Scholar
  5. 5.
    Polin RA, Carlo WA, Committee on Fetus and Newborn, American Academy of Pediatrics (2014) Surfactant replacement therapy for preterm and term neonates with respiratory distress. Pediatrics 133:156–163. https://doi.org/10.1542/peds.2013-3443CrossRefPubMedGoogle Scholar
  6. 6.
    Monto AS, Paul Robinson D, Louise Herlocher M, Hinson JM Jr, Elliott MJ, Crisp A (1999) Zanamivir in the prevention of influenza among healthy adults. JAMA 282:31. https://doi.org/10.1001/jama.282.1.31CrossRefPubMedGoogle Scholar
  7. 7.
    Chan HK, Chew NY (2003) Novel alternative methods for the delivery of drugs for the treatment of asthma. Adv Drug Deliv Rev 55:793–805CrossRefGoogle Scholar
  8. 8.
    Johnson MA, Newman SP, Bloom R, Talaee N, Clarke SW (1989) Delivery of albuterol and ipratropium bromide from two nebulizer systems in chronic stable asthma. Chest 96:6–10. https://doi.org/10.1378/chest.96.1.6CrossRefPubMedGoogle Scholar
  9. 9.
    Mahler DA, Wire P, Horstman D, Chang C-N, Yates J, Fischer T, Shah T (2002) Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 166:1084–1091. https://doi.org/10.1164/rccm.2112055CrossRefPubMedGoogle Scholar
  10. 10.
    Acerbi D, Brambilla G, Kottakis I (2007) Advances in asthma and COPD management: delivering CFC-free inhaled therapy using Modulite® technology. Pulm Pharmacol Ther 20:290–303. https://doi.org/10.1016/j.pupt.2006.05.005CrossRefPubMedGoogle Scholar
  11. 11.
    Santos Cavaiola T, Edelman S (2014) Inhaled insulin: a breath of fresh air? A review of inhaled insulin. Clin Ther 36:1275–1289. https://doi.org/10.1016/j.clinthera.2014.06.025CrossRefPubMedGoogle Scholar
  12. 12.
    Traynor K (2014) Inhaled insulin product approved. Am J Health-Syst Pharm 71:1238. https://doi.org/10.2146/news140052CrossRefPubMedGoogle Scholar
  13. 13.
    Price DN, Kusewitt DF, Lino CA, McBride AA, Muttil P (2016) Oral tolerance to environmental mycobacteria interferes with intradermal, but not pulmonary, immunization against tuberculosis. PLOS Pathog 12:e1005614. https://doi.org/10.1371/journal.ppat.1005614CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    McBride AA, Price DN, Lamoureux LR, Elmaoued AA, Vargas JM, Adolphi NL, Muttil P (2013) Preparation and characterization of novel magnetic nano-in-microparticles for site-specific pulmonary drug delivery. Mol Pharm 10:3574–3581. https://doi.org/10.1021/mp3007264CrossRefPubMedGoogle Scholar
  15. 15.
    Price DN, Muttil P (2016) Directed intervention and immunomodulation against pulmonary tuberculosis. In: Drug delivery systems for tuberculosis prevention and treatment. John Wiley & Sons, Ltd, Chichester, pp 346–377. https://doi.org/10.1002/9781118943182.ch18CrossRefGoogle Scholar
  16. 16.
    Yi D, Wiedmann TS (2010) Inhalation adjuvant therapy for lung cancer. J Aerosol Med Pulm Drug Deliv 23:181–187. https://doi.org/10.1089/jamp.2009.0787CrossRefPubMedGoogle Scholar
  17. 17.
    Zarogoulidis P, Darwiche K, Krauss L, Huang H, Zachariadis GA, Katsavou A, Hohenforst-Schmidt W et al (2013) Inhaled cisplatin deposition and distribution in lymph nodes in stage II lung cancer patients. Future Oncol 9:1307–1313. https://doi.org/10.2217/fon.13.111CrossRefPubMedGoogle Scholar
  18. 18.
    Tatsumura T, Koyama S, Tsujimoto M, Kitagawa M, Kagamimori S (1993) Further study of nebulisation chemotherapy, a new chemotherapeutic method in the treatment of lung carcinomas: fundamental and clinical. Br J Cancer 68:1146–1149CrossRefGoogle Scholar
  19. 19.
    Gagnadoux F, Hureaux J, Vecellio L, Urban T, Le Pape A, Valo I, Montharu J et al (2008) Aerosolized chemotherapy. J Aerosol Med Pulm Drug Deliv 21:61–70. https://doi.org/10.1089/jamp.2007.0656CrossRefPubMedGoogle Scholar
  20. 20.
    Lemarie E, Vecellio L, Hureaux J, Prunier C, Valat C, Grimbert D, Boidron-Celle M et al (2011) Aerosolized gemcitabine in patients with carcinoma of the lung: feasibility and safety study. J Aerosol Med Pulm Drug Deliv 24:261–270. https://doi.org/10.1089/jamp.2010.0872CrossRefPubMedGoogle Scholar
  21. 21.
    Garcia-Contreras L, Wong Y-L, Muttil P, Padilla D, Sadoff J, Derousse J, Germishuizen WA et al (2008) Immunization by a bacterial aerosol. Proc Natl Acad Sci U S A 105:4656–4660. https://doi.org/10.1073/pnas.0800043105CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Otterson GA, Villalona-Calero MA, Sharma S, Kris MG, Imondi A, Gerber M, White DA et al (2007) Phase I study of inhaled doxorubicin for patients with metastatic tumors to the lungs. Clin Cancer Res 13:1246–1252. https://doi.org/10.1158/1078-0432.CCR-06-1096CrossRefPubMedGoogle Scholar
  23. 23.
    Otterson GA, Villalona-Calero MA, Hicks W, Pan X, Ellerton JA, Gettinger SN, Murren JR (2010) Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer. Clin Cancer Res 16:2466–2473. https://doi.org/10.1158/1078-0432.CCR-09-3015CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Gonda I (2006) Systemic delivery of drugs to humans via inhalation. J Aerosol Med 19:47–53. https://doi.org/10.1089/jam.2006.19.47CrossRefPubMedGoogle Scholar
  25. 25.
    Nahar K, Gupta N, Gauvin R, Absar S, Patel B, Gupta V, Khademhosseini A, Ahsan F (2013) In vitro, in vivo and ex vivo models for studying particle deposition and drug absorption of inhaled pharmaceuticals. Eur J Pharm Sci 49:805–818. https://doi.org/10.1016/j.ejps.2013.06.004CrossRefPubMedGoogle Scholar
  26. 26.
    Boegh M, Foged C, Müllertz A, Mørck Nielsen H (2013) Mucosal drug delivery: barriers, in vitro models and formulation strategies. J Drug Deliv Sci Technol 23:383–391. https://doi.org/10.1016/S1773-2247(13)50055-4CrossRefGoogle Scholar
  27. 27.
    Mathias NR, Hussain MA (2010) Non-invasive systemic drug delivery: developability considerations for alternate routes of administration. J Pharm Sci 99:1–20. https://doi.org/10.1002/jps.21793CrossRefPubMedGoogle Scholar
  28. 28.
    Courrier HM, Butz N, Vandamme TF (2002) Pulmonary drug delivery systems: recent developments and prospects. Crit Rev Ther Drug Carrier Syst 19:425–498. https://doi.org/10.1615/CritRevTherDrugCarrierSyst.v19.i45.40CrossRefPubMedGoogle Scholar
  29. 29.
    Labiris NR, Dolovich MB (2003) Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 56:588–599. https://doi.org/10.1046/j.1365-2125.2003.01892.xCrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Dorato MA (1990) Overview of inhalation toxicology. Environ Health Perspect 85:163–170CrossRefGoogle Scholar
  31. 31.
    Cryan S-A, Sivadas N, Garcia-Contreras L (2007) In vivo animal models for drug delivery across the lung mucosal barrier. Adv Drug Deliv Rev 59:1133–1151. https://doi.org/10.1016/j.addr.2007.08.023CrossRefPubMedGoogle Scholar
  32. 32.
    Wong BA (2007) Inhalation exposure systems: design, methods and operation. Toxicol Pathol 35:3–14. https://doi.org/10.1080/01926230601060017CrossRefPubMedGoogle Scholar
  33. 33.
    Forbes B, Asgharian B, Dailey LA, Ferguson D, Gerde P, Gumbleton M, Gustavsson L et al (2011) Challenges in inhaled product development and opportunities for open innovation. Adv Drug Deliv Rev 63:69–87. https://doi.org/10.1016/j.addr.2010.11.004CrossRefPubMedGoogle Scholar
  34. 34.
    Bivas-Benita M, Zwier R, Junginger H, Borchard G (2005) Non-invasive pulmonary aerosol delivery in mice by the endotracheal route. Eur J Pharm Biopharm 61:214–218. https://doi.org/10.1016/j.ejpb.2005.04.009CrossRefPubMedGoogle Scholar
  35. 35.
    Das S, MacDonald K, Chang H-YS, Mitzner W (2013) A simple method of mouse lung intubation, J Vis Exp:e50318. https://doi.org/10.3791/50318
  36. 36.
    MacDonald KD, Chang H-YS, Mitzner W (2009) An improved simple method of mouse lung intubation. J Appl Physiol (1985) 106:984–987. https://doi.org/10.1152/japplphysiol.91376.2008CrossRefGoogle Scholar
  37. 37.
    Morello M, Krone CL, Dickerson S, Howerth E, Germishuizen WA, Wong Y-LL, Edwards D, Bloom BR, Hondalus MK (2009) Dry-powder pulmonary insufflation in the mouse for application to vaccine or drug studies. Tuberculosis (Edinb) 89:371–377. https://doi.org/10.1016/j.tube.2009.07.001CrossRefGoogle Scholar
  38. 38.
    Caracas HC, Maciel JV, Martins PM, de Souza MM, Maia LC (2009) The use of lidocaine as an anti-inflammatory substance: a systematic review. J Dent 37:93–97. https://doi.org/10.1016/j.jdent.2008.10.005CrossRefPubMedGoogle Scholar
  39. 39.
    Price DN, Stromberg LR, Kunda NK, Muttil P (2017) In vivo pulmonary delivery and magnetic-targeting of dry powder nano-in-microparticles. Mol Pharm. https://doi.org/10.1021/acs.molpharmaceut.7b00532. [Epub ahead of print]

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Pharmaceutical Sciences, College of PharmacyUniversity of New MexicoAlbuquerqueUSA

Personalised recommendations